Hydrogels for the Treatment of Myocardial Infarction : Design and Therapeutic Strategies
© 2023 Wiley-VCH GmbH..
Cardiovascular diseases (CVDs) have become the leading global burden of diseases in recent years and are the primary cause of human mortality and loss of healthy life expectancy. Myocardial infarction (MI) is the top cause of CVDs-related deaths, and its incidence is increasing worldwide every year. Recently, hydrogels have garnered great interest from researchers as a promising therapeutic option for cardiac tissue repair after MI. This is due to their excellent properties, including biocompatibility, mechanical properties, injectable properties, anti-inflammatory properties, antioxidant properties, angiogenic properties, and conductive properties. This review discusses the advantages of hydrogels as a novel treatment for cardiac tissue repair after MI. The design strategies of various hydrogels in MI treatment are then summarized, and the latest research progress in the field is classified. Finally, the future perspectives of this booming field are also discussed at the end of this review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Macromolecular bioscience - 24(2024), 2 vom: 14. Feb., Seite e2300302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liang, Jiaheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac tissue engineering |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mabi.202300302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363086722 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363086722 | ||
| 003 | DE-627 | ||
| 005 | 20240219231902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mabi.202300302 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM363086722 | ||
| 035 | |a (NLM)37815522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liang, Jiaheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydrogels for the Treatment of Myocardial Infarction |b Design and Therapeutic Strategies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Cardiovascular diseases (CVDs) have become the leading global burden of diseases in recent years and are the primary cause of human mortality and loss of healthy life expectancy. Myocardial infarction (MI) is the top cause of CVDs-related deaths, and its incidence is increasing worldwide every year. Recently, hydrogels have garnered great interest from researchers as a promising therapeutic option for cardiac tissue repair after MI. This is due to their excellent properties, including biocompatibility, mechanical properties, injectable properties, anti-inflammatory properties, antioxidant properties, angiogenic properties, and conductive properties. This review discusses the advantages of hydrogels as a novel treatment for cardiac tissue repair after MI. The design strategies of various hydrogels in MI treatment are then summarized, and the latest research progress in the field is classified. Finally, the future perspectives of this booming field are also discussed at the end of this review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cardiac tissue engineering | |
| 650 | 4 | |a cardiac tissue repair | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a hydrogels | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 700 | 1 | |a Lv, Ronghao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Maorui |e verfasserin |4 aut | |
| 700 | 1 | |a Chai, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shuo |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Wenjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Zijian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Macromolecular bioscience |d 2004 |g 24(2024), 2 vom: 14. Feb., Seite e2300302 |w (DE-627)NLM151409706 |x 1616-5195 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:2 |g day:14 |g month:02 |g pages:e2300302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mabi.202300302 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 2 |b 14 |c 02 |h e2300302 | ||